Postmarket Safety Actions for Novel Oncology Drugs Granted FDA’s Accelerated Approval
This cross-sectional study examines postmarket safety actions for novel oncology drugs that received accelerated Food and Drug Administration (FDA) approval.
Authors
- Paula P. Schnurr (ORCID: https://orcid.org/0000-0002-6195-716X)
- J D Wallach
- Maryam Mooghali (ORCID: https://orcid.org/0000-0001-9347-494X)
- Reshma Ramachandran
- Aaron P. Mitchell
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Emory University (US)
- Yale University (US)
- Yale New Haven Health System (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.53764
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Yale University
- Arnold Ventures